Light Chain (AL) Amyloidosis research hub

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

This study is looking into a new treatment called birtamimab for people with a serious heart condition called AL amyloidosis. Researchers want to see if birtamimab, given with standard care, can help people live longer compared to standard care alone.